Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Protagonist Therapeutics Inc (NQ: PTGX )

26.25 +0.89 (+3.51%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 899,074
Open 25.29
Bid (Size) 25.36 (10)
Ask (Size) 27.46 (14)
Prev. Close 25.36
Today's Range 24.50 - 26.45
52wk Range 6.910 - 26.87
Shares Outstanding 57,251,254
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Promising Phase 1 Results: Protagonist Therapeutics and Janssen Biotech Unlock New Potential in Colitis and Inflammation Treatment
Protagonist Therapeutics (NASDAQ: PTGX) reported data from its collaboration with Janssen Biotech Inc, a unit of Johnson & Johnson (NYSE: JNJ), on Phase 1 and preclinical studies of  
Via Benzinga
Protagonist, A Top 1% Biotech, Briefly Breaks Out On Psoriasis Enthusiasm
The company is targeting psoriasis with a first-ever mechanism that could rival leaders. 
Via Investor's Business Daily

Performance

YTD
+143.51%
+143.51%
1 Month
+16.15%
+16.15%
3 Month
+61.34%
+61.34%
6 Month
+256.66%
+256.66%
1 Year
+199.66%
+199.66%

More News

Read More
Protagonist Therapeutics: Q1 Earnings Insights
Via Benzinga
4 Analysts Have This to Say About Protagonist Therapeutics
Via Benzinga
Why Shares of Protagonist Therapeutics Rose This Week
Via The Motley Fool
Why Protagonist Therapeutics Shares Are Nosediving
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Protagonist Therapeutics Touts Positive Data From Bone Marrow Disorder Study
Via Benzinga
Why Protagonist Therapeutics Shares Are Trading Higher Today
Via Benzinga
Protagonist Therapeutics Announces Pricing of $100 Million Public Offering of Shares of Common Stock
Via ACCESSWIRE
Protagonist Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
Via ACCESSWIRE
Protagonist Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Via ACCESSWIRE
Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera
Via ACCESSWIRE
Top 5 Health Care Stocks That Are Ticking Portfolio Bombs
Via Benzinga
Why Rivian Automotive Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Dick's Sporting Goods, WW International, Sea Limited And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Top 5 Health Care Stocks That May Collapse In February
Via Benzinga
Protagonist Therapeutics Earnings Perspective: Return On Capital Employed
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shareholder Alert: Investigation over Possible Wrongdoing
Via SBWire
3 Biotech Stocks to Buy Before They Boom
Via InvestorPlace
The Daily Biotech Pulse: INmune Bio's Planned Alzheimer's Trial On FDA Hold, Caladrius Stops Enrollment In Heart Disease Study, BiomX Restructures
Via Benzinga
The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More
Via Benzinga
7 Micro-Cap Stocks to Buy and Hold for the Next 10 Years
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.